Pick of the day
RougeTx
A Dutch biotech spinout from Leiden University Medical Center developing an oral, disease-modifying therapy for hereditary hemorrhagic telangiectasia, a rare bleeding disorder with no approved treatments.
- Problem
- 8
- Traction
- 4
- Founders
- 7
- Market
- 6
- Novelty
- 7
Why today
Today's pick is RougeTx, the Dutch biotech spinout from Leiden University Medical Center that launched October 6, 2026 with a 58 million dollar Series A led by BioGeneration Ventures and Angelini Ventures, joined by the European Investment Bank's Aurea co-investment facility and Kurma Partners. Against a quieter stretch of funding news that included a 668 million dollar equity-and-debt package for a Taiwanese GPU cloud provider, a 251 million dollar Series D for a company that manufactures medicines in orbit, a 38 million dollar Series A for a Miami startup building private networks for AI agents, and a roughly 13 million dollar Series B for a Bengaluru kitchen-appliance maker, RougeTx stands out because it is going after a disease with zero approved treatments anywhere in the world, backed by science built over two decades and a nine-investor syndicate deep enough to signal real conviction in an otherwise unproven preclinical asset.
Problem
Hereditary hemorrhagic telangiectasia is an inherited vascular disorder in which fragile, poorly supported blood vessels rupture easily, causing chronic nosebleeds, gastrointestinal bleeding and arteriovenous malformations in the lungs, liver and brain. No therapy is approved by the FDA or the European Medicines Agency anywhere in the world for the condition, leaving patients and physicians reliant on supportive measures such as iron infusions, blood transfusions and repeated cauterization procedures. The closest systemic option, the cancer drug bevacizumab, is used off-label, lacks a standardized dosing protocol, and loses its effect once treatment stops.
Product
RougeTx's lead candidate, RTX-001, is an oral small molecule designed to restore the attachment of pericytes, the mural cells that wrap around capillaries and keep vessel walls stable, a mechanism the company believes addresses the root cause of HHT's fragile blood vessels rather than just controlling bleeding after it starts. The company is pairing RTX-001 with a discovery platform it calls periSCOPE, built on the same pericyte biology, which it intends to use to identify further drug candidates for other diseases where unstable blood vessels drive disease, extending the approach beyond HHT over time.
Traction
RougeTx is still preclinical, so it has no patient data yet; its traction so far is institutional rather than clinical. The company is a direct spinout of more than two decades of pericyte research led by co-founder Franck Lebrin at Inserm and Leiden University Medical Center, and its Series A drew nine separate investors, including a development-bank co-investment facility and a corporate venture arm tied to a listed pharmaceutical company. The new capital is earmarked for a planned, well-powered, double-blind, placebo-controlled Phase IIa trial, the company's first attempt to show the mechanism works in actual HHT patients.
Team
RougeTx is led by chief executive Andrew Lightfoot, who has pointed to HHT's lack of approved treatments as the gap the company exists to close. Its scientific foundation traces to co-founder and scientific adviser Franck Lebrin, whose pericyte-biology research at Inserm and Leiden University Medical Center over more than twenty years underpins RTX-001 and the periSCOPE platform. The company launched directly out of LUMC's spin-off process rather than years in stealth, giving it an academic pedigree in vascular biology but a leadership team still largely unproven at running a venture-backed clinical-stage biotech through trials.
Funding
RougeTx's 58 million dollar Series A was announced October 6, 2026, co-led by founding investor BioGeneration Ventures and Angelini Ventures, with the European Investment Bank's Aurea co-investment facility and Kurma Partners also investing. Epidarex Capital, Vesalius Biocapital Partners, ROM Utrecht Region, p53 Invest and Kerna Ventures rounded out the syndicate. The round marks the fourth joint investment by Angelini Ventures and the EIB under a 150 million euro partnership aimed at European biotech, medtech and digital health companies, giving RougeTx a strategic pharmaceutical backer alongside specialist life-science investors as it heads toward its first clinical trial.
Competitors
RougeTx has no approved-drug competitor: HHT has zero FDA- or EMA-approved therapies. The nearest thing to standard care is bevacizumab, a cancer antibody used off-label against VEGF, which raises hemoglobin and reduces nosebleed severity in observational studies but has no standardized dosing, requires ongoing treatment to sustain any benefit, and was built for oncology rather than vascular stability. By targeting pericyte attachment directly with an oral small molecule rather than repurposing a biologic, RougeTx is betting on a different mechanism entirely, though it will need its own trial data before it can claim an advantage over bevacizumab's decade of off-label use.
VC lens
Would YC fund it? Mixed: a disease with zero approved treatments and two decades of academic groundwork is a real wedge, but a preclinical asset with no human data yet is exactly the kind of long, capital-intensive bet that sits outside YC's usual speed-to-traction bar.
Biggest risk: RougeTx has not yet tested RTX-001 in a single HHT patient, and pericyte-targeting drugs have a thin track record of translating from animal models into human vascular disease. If the planned Phase IIa trial fails to show a mechanistic effect on bleeding, the company will have spent a 58 million dollar round without clinical proof of concept, in a disease area where several biologics have already failed to earn approval.
Runners-up
GMI Cloud
668 million dollar equity-and-debt package, a 223 million dollar Series B led by ARCHIV plus a 445 million dollar credit facility from CTBC, for the Taiwan-based GPU cloud provider expanding AI infrastructure capacity and hiring across Asia-Pacific, with Nvidia among the backers. (Sep 30)
Varda Space Industries
251 million dollar Series D led by Lux Capital and Natural Capital at a 1.6 billion dollar valuation, for the El Segundo company that manufactures medicines aboard reentry capsules in microgravity, lifting its total funding to roughly 598 million dollars. (Sep 30)
doxx.net
38 million dollar Series A led by Andreessen Horowitz for the Miami startup building private, policy-controlled networks that let AI agents browse and transact while blocking known malicious destinations. (Oct 1)
Beyond Appliances
110 crore rupee, roughly 13 million dollar, Series B led by Fireside Ventures for the Bengaluru smart-kitchen-appliance maker, which plans to open a new manufacturing plant and expand into new appliance categories. (Oct 6)
Archive
38 reports · click a row to open it| Date | Winner | One-liner | Runners-up | Open |
|---|---|---|---|---|
| 2026-10-19 | Modal Labs | 750 million dollar Series D led by Accel at a 15.75 billion dollar valuation, as the AI infrastructure startup says its annualized run rate crossed 1 billion dollars with usage tripling in five months, built on serverless GPU access for inference, training and agent sandboxes | OMass Therapeutics, Scanntech, North.cloud, Fortem Technologies | |
| 2026-10-18 | Mueon | 65 million dollar Series A led by Maverick Silicon, as the Portland semiconductor startup founded by two Intel veterans scales Cubelets, modular 3D blocks bundling compute, memory, power and cooling to cut AI data center power and density limits, already in use by AI chip startup d-Matrix | Estuary Biotherapeutics, Fission, Otter Health, HyLight | |
| 2026-10-17 | Chariot Claims | 10 million dollar Series A led by Silverton Partners, as the rebranded ClaimClam legal-tech platform scales automated matching of consumers to mass arbitration and class-action claims over hidden fees and hard-to-cancel subscriptions, building on more than 65,000 claims already processed toward an estimated 92 million dollars in settlements | Marklo, Siena, Rein Security, Peppermint | |
| 2026-10-16 | Salience Labs | 125 million dollar oversubscribed Series B led by Bullhound Capital, as the Oxford-spun-out photonics company wins new backing from AMD Ventures and Intel Capital for all-optical circuit switches meant to break the power and latency ceiling facing electronic switches as AI GPU clusters scale toward tens of thousands of chips | Navra, Type One Energy, Oratomic, Gallatin AI | |
| 2026-10-15 | Soufflé Therapeutics | 135 million dollar Series B led by Juvia Group, as the MIT bioengineer Robert Langer-founded biotech works to deliver RNA medicines to muscle and heart tissue, a problem that has stalled the entire siRNA drug class, backed by more than 3.5 billion dollars in big pharma partnerships before any program has reached the clinic | ICON, Pluto Security, Nous Research, Atomic Machines | |
| 2026-10-14 | Vitalize | 31 million dollar Series A led by Oak HC and FT, as the Y Combinator-backed startup unifying hospital staffing, scheduling, patient flow and capacity management expands after enterprise customers reported cutting manual scheduling work and premium labor spend | Gallatin AI, byteXL, Desible.ai, Credfix | |
| 2026-10-13 | Universal Quantum | 100 million dollar Series A co-led by DCVC and Firgun Ventures, a record raise for a UK quantum computing company, as the University of Sussex spinout races to prove its modular trapped-ion chiplet interconnect can out-scale newly public rivals Quantinuum and IonQ | Atlas Atomics, Type One Energy, Sabi, Catalyst | |
| 2026-10-12 | Manus | 500 million dollar funding round led by Boyu Capital and IDG Capital, the general AI agent's first raise since China blocked Meta's 2 billion dollar bid for the company and barred its founders from leaving the country, as Manus pursues a reported 4 billion dollar valuation on roughly 125 million dollars of annualized revenue | Oratomic, Matchpoint Therapeutics, Oxide Computer, Stuut | |
| 2026-10-11 | Arena | 200 million dollar Series B co-led by Lightspeed Venture Partners and Khosla Ventures at a 3.1 billion dollar valuation, as the company behind the Chatbot Arena leaderboard nearly doubles its valuation in ten months on roughly 100 million dollars of annualized revenue from selling AI evaluation and alignment benchmarking to labs and enterprises, while Scale AI's new Seal Showdown contests its neutral-referee position | Gallatin AI, Rein Security, Rivercell, TeddyHoldings.AI | |
| 2026-10-10 | Multiply Labs | 75 million dollar Series B led by Patrick Soon-Shiong's NantWorks with new investors AstraZeneca, Lingotto, Teradyne and Strange Ventures, as the decade-old biologics-manufacturing robotics company passes 100 million dollars raised on the strength of its first commercial sale, an up to 85 million dollar deal with Retro Biosciences, while competing against well-funded rivals Cellares and Ori Biotech to automate cell and gene therapy production | Zomint, Parakeet Health, OuterSignal, Efficient Computer | |
| 2026-10-09 | RougeTx | 58 million dollar Series A led by BioGeneration Ventures and Angelini Ventures with the European Investment Bank's Aurea facility and Kurma Partners also investing, as the Leiden University Medical Center spinout launches the first disease-modifying candidate for hereditary hemorrhagic telangiectasia, a bleeding disorder with no approved therapies, built on more than two decades of pericyte research | GMI Cloud, Varda Space Industries, doxx.net, Beyond Appliances | |
| 2026-10-08 | General Medicine | 120 million dollar Series B led by Andreessen Horowitz with Eli Lilly and Mercy Health joining, as the PillPack founders' online healthcare marketplace brings total funding to 152 million dollars less than three years after launch on hundreds of thousands of customers and an 80 Net Promoter Score | Noah, Nous Research, Buntar Aerospace, Monid | |
| 2026-10-07 | Vinci | 250 million dollar Series B at a 1.5 billion dollar valuation co-led by Advent, Temasek and Xora Innovation, as the Palo Alto physics foundation model startup jumps from a 46 million dollar seed and Series A disclosed last December to a tenfold valuation leap less than a year later, aiming its technology at chip design incumbents Cadence and Synopsys | Spiko, Hadrian, WhiteLab Genomics, Inbolt | |
| 2026-10-06 | Pandektes | 13.5 million euro Series A led by Munich's Alstin Capital, as the Copenhagen legal-research startup grows revenue sixfold and wins customers switching off LexisNexis, Westlaw, Beck and Karnov with an API-first legal data platform | OneByZero, Fleuret AI, Laki Power, RobCo | |
| 2026-10-05 | PaleBlueDot AI | 200 million dollar Series C at a 3.2 billion dollar valuation led by ComputeCore, as the Palo Alto AI compute platform nearly triples its valuation in under nine months on more than 5 billion dollars of signed customer contracts | Simple Energy, Elio Mortgage, Menos AI, SedMed | |
| 2026-10-04 | Flow Engineering | 50 million dollar Series B at a 750 million dollar valuation co-led by Valor Equity Partners and Atreides Management, as the AI-native systems-engineering platform for hardware teams grows to over 100 million requirements managed and adds General Motors, Anduril and Intuitive Machines as customers less than a year after its Series A | Miter, Kanu AI, Beltic, Satlyt | |
| 2026-10-03 | EliseAI | 350 million dollar round at a 4 billion dollar valuation led by Andreessen Horowitz and Bessemer Venture Partners, as the housing and healthcare conversational AI company nearly doubles its valuation in thirteen months on 200 million dollars of ARR and five straight years of 100 percent revenue growth | Kahua, Breye Therapeutics, Amara, Kuro | |
| 2026-10-02 | Armadin | 255.5 million dollar Series B co-led by Andreessen Horowitz and Accel at a 2.5 billion dollar valuation, as Mandiant founder Kevin Mandia's agentic attacker-swarm security platform runs live attack campaigns for Fortune 500 and government customers seven months after stealth | Foundational, Seeds Fincap, Numeral, Chamelio | |
| 2026-10-01 | General Intuition | 220 million dollar Series B at a 6.2 billion dollar valuation, nearly tripling in three months, as the AI foundation model startup trains action models on billions of gameplay clips from its own sister company Medal | Varda, Jeeves, Sand.ai, Arivihan | |
| 2026-09-30 | Tiny Health | Oversubscribed $33M Series B led by B Capital as the at-home microbiome testing company posts 1,624% three-year revenue growth and quadruples its practitioner-facing business | Modulate, erad, Baselayer, Ande | |
| 2026-09-29 | Instinct | $1B Series C led by Sequoia, Benchmark and Coatue at a $10B valuation, a roughly 4x jump in five weeks, as its text-message AI agent passes 100,000 users with 10% daily compounding growth | SiMa.ai, Quartermaster, Outmarket AI, Humanos | |
| 2026-09-28 | Solcoa Industries | $75M seed ($45M equity led by Bain Capital Ventures plus $30M JPMorgan-anchored debt) to build a 500-tonne Nevada plant using a novel rare-earth metalmaking process, aimed at breaking China's 95% grip on metallization | Clastix, Prevision Medicine, Spiich, Barq | |
| 2026-09-27 | Ultraviolette | $85M Series E led by Yali Capital and TDK Ventures; Bengaluru performance EV motorcycle maker plans US entry by 2027 on 4-5x revenue growth | Micro1, Kasvu Therapeutics, HIFI, Dextr AI | |
| 2026-09-26 | Island | $400M Series F led by Evolution Equity Partners at a $6.4B valuation, more than doubling its 2024 valuation as the enterprise browser expands into governing AI agents | Cyera, Confido, Heidi Health, Firecrawl | |
| 2026-09-25 | Ema | $77M Series B led by Creaegis, more than quadrupling its valuation as every existing backer doubled down and Wipro scales its AI Employees to 240,000+ workers | Ando, Kasvu Therapeutics, HIFI, Nuvah | |
| 2026-09-24 | TEKEVER | $580M Series D led by UC Investments and Baillie Gifford; Ukraine-proven AI surveillance drone maker hits $6.4B valuation on a new 400M pound UK Army contract | Enveda Biosciences, Basecamp Research, Numeral, Brahma AI | |
| 2026-09-23 | Verda | $189M oversubscribed Series B led by Emergence Capital; profitable Nordic GPU cloud crosses $1B valuation on $165M ARR | Snorkel AI, Nexstrom, MacroCycle, Demoverse | |
| 2026-09-22 | BCI-Sonics | RMB 200M (~$30M) Pre-Series A led by HSG and Yunqi Capital; non-invasive ultrasound brain-computer interface racing China's invasive BCI leaders and OpenAI-backed Merge Labs | Spott, HighLife, CellPoint, Benford | |
| 2026-09-22 | Amber Electric | €49M Series E led by Morgan Stanley's 1GT; automates 50%+ of Australia's home batteries, expanding VPP software into Europe via E.ON | Corridor, Paymob, Unit1 Studio, Drivn | |
| 2026-09-18 | TypeSafe AI | $40M seed led by DCVC; "System One" model returns typed decisions for software, not chat — built by RLHF co-inventor Diogo Almeida | Space Epoch, Facilo, Treble Technologies, DheyaTech | |
| 2026-09-17 | Exein | $270M Series C at $1.7B valuation (30x in 2 yrs); kernel-level security layer for robots, drones and autonomous machines | Anew Labs, Delos Data, CADDi, AIUC | |
| 2026-09-16 | Euclyd | €200M+ Series A; Samsung-backed (investor + manufacturer) AI inference chip built to out-efficiency Nvidia, chaired by ex-ASML CEO | Profound, Flam, ENCOS, Nutshell Therapeutics | |
| 2026-09-15 | Fortaegis | $50M oversubscribed Series A; quantum-safe security rooted in silicon, chaired by Quantinuum founder Ilyas Khan | Qupital, Tandem Health, Atomarine, UniqYou | |
| 2026-09-11 | Positron AI | $875M Series C at $5B valuation; memory-first inference chips challenging Nvidia's HBM lock-in | The Boring Company, Mach Industries, Rogo Technologies, Swish | |
| 2026-09-10 | Cognition AI | $2B+ Series E at $48B valuation; Devin autonomous coding agent nears $900M run-rate | DigitalPaani, Algomatic Dynamics, Limetax, Fundly.ai | |
| 2026-09-09 | Bluecore Energy | Floating nuclear reactor barges for ports; $50M seed just 2 months after stealth launch | QNu Labs, ARC Ride, Circolife, Hope Care | |
| 2026-09-08 | Pixxel | $100M Series C, India's largest spacetech round; building orbital AI data centers | Nua, Navana.ai, GalaxEye, Atoms (Kalanick) | |
| 2026-09-07 | Medulance | GPS-dispatched ambulance network raises ₹24 Cr Series A-2 | Comet, Mokobara, Kit (Speakeasy), XDOF |
Sources
- GlobeNewswire — RougeTx Launches with $58 Million Series A Financing to Advance First-in-Class Treatment for Hereditary Hemorrhagic Telangiectasia
- BioXconomy — RougeTx raises $58m to take on hereditary bleeding disorder
- European Biotechnology Magazine — RougeTx launches with $58M to tackle rare bleeding disorder
- AllSci — RougeTx Funding Raises USD 58M Series A to Push RTX-001 Toward the Clinic
- Teleborsa via Borsa Italiana — Angelini Ventures e BEI investono in RougeTx
- reNEW — RougeTx advances therapy for inherited bleeding disorder HHT
- People Matters — GMI Cloud raises $668M to expand AI infrastructure and hiring across APAC
- Cooley — Varda Announces $251 Million Series D
- SecurityWeek — doxx.net Raises $38 Million to Prevent AI Agent On-The-Internet Misadventures
- YourStory — Beyond Appliances raises Rs 110 Cr in Series B round led by Fireside Ventures
Compiled from search results: article pages were unreachable from the publishing environment on this date, so every fact here was cross-checked against at least two independent reports.